Standpoint Research Starts Coherus Biosciences (CHRS) at Buy
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.15 -4.17%
Rating Summary:
11 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 23 | New: 22
Rating Summary:
11 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 23 | New: 22
Join SI Premium – FREE
Standpoint Research initiates coverage on Coherus Biosciences (NASDAQ: CHRS) with a Buy rating and a price target of $40.00.
For an analyst ratings summary and ratings history on Coherus Biosciences click here. For more ratings news on Coherus Biosciences click here.
Shares of Coherus Biosciences closed at $28.10 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights
- H.C. Wainwright Assumes Alpha Compute Corp. (ALP) at Neutral
- Needham Starts Pulse Biosciences (PLSE) at Buy
Create E-mail Alert Related Categories
New CoverageRelated Entities
Standpoint ResearchSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
